Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0P5BY
|
||||
| Former ID |
DNC006135
|
||||
| Drug Name |
N-(cyanomethyl)cyclohex-1-ene-1-carboxamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C9H12N2O
|
||||
| Canonical SMILES |
C1CCC(=CC1)C(=O)NCC#N
|
||||
| InChI |
1S/C9H12N2O/c10-6-7-11-9(12)8-4-2-1-3-5-8/h4H,1-3,5,7H2,(H,11,12)
|
||||
| InChIKey |
ZVHMBSSCZBPAIY-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Cathepsin K | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Lysosome | ||||
| Osteoclast differentiation | |||||
| Toll-like receptor signaling pathway | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| RANKL Signaling Pathway | |||||
| IL2 Signaling Pathway | |||||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| Trafficking and processing of endosomal TLR | |||||
| MHC class II antigen presentation | |||||
| WikiPathways | RANKL/RANK Signaling Pathway | ||||
| Osteoclast Signaling | |||||
| References | |||||
| REF 1 | J Med Chem. 2006 Feb 9;49(3):1066-79.Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.